Regulation of BCRP/ABCG2 expression by progesterone and 17β-estradiol in human placental BeWo cells

American Journal of Physiology - Endocrinology and Metabolism

Volumn 290, Issue 5, 2006, Pages

  Wang, Honggang ^a   Zhou, Lin ^a   Gupta, Anshul ^a   Vethanayagam, R Robert ^a   Zhang, Yi ^a   Unadkat, Jashvant D ^a   Mao, Qingcheng ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ATP binding cassette transporter; Hormonal regulation; Pregnancy

Indexed keywords

ANTIGESTAGEN; BREAST CANCER RESISTANCE PROTEIN; ESTRADIOL RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; FUMITREMORGIN C; INDOLE DERIVATIVE; MESSENGER RNA; MIFEPRISTONE; MITOXANTRONE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; UNCLASSIFIED DRUG;

ARTICLE; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; PLACENTA; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIFEPRISTONE; MITOXANTRONE; NEOPLASM PROTEINS; PLACENTA; PREGNANCY; PROGESTERONE; RECEPTORS, PROGESTERONE;

EID: 33646390931     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00397.2005     Document Type: Article

References (36)

1. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, and Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58: 5337-5339, 1998.
2. Bailey-Dell KJ, Hassel B, Doyle LA, and Ross DD. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 1520: 234-241, 2001.
3. Batra S and Bengtsson LP. 17 beta-Estradiol and progesterone concentrations in myometrium of pregnancy and their relationships to concentrations in peripheral plasma. J Clin Endocrinol Metab 46: 622-626, 1978.
4. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, and Schellens JH. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 64: 5804-5811, 2004.
5. Cao J, Stieger B, Meier PJ, and Vore M. Expression of rat hepatic multidrug resistance-associated proteins and organic anion transporters in pregnancy. Am J Physiol Gastrointest Liver Physiol 283: G757-G766, 2002.
6. Cheng G, Li Y, Omoto Y, Wang Y, Berg T, Nord M, Vihko P, Warner M, Piao YS, and Gustafsson JA. Differential regulation of estrogen receptor (ER)alpha and ERbeta in primate mammary gland. J Clin Endocrinol Metab 90: 435-444, 2005.
7. Christensen K, Estes PA, Onate SA, Beck CA, DeMarzo A, Altmann M, Lieberman BA, St John J, Nordeen SK, and Edwards DP. Characterization and functional properties of the A and B forms of human progesterone receptors synthesized in a baculovirus system. Mol Endocrinol 5: 1755-1770, 1991.
8. Doyle LA and Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358, 2003.
9. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665-15670, 1998.
10. Ee PL, He X, Ross DD, and Beck WT. Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol Cancer Ther 3: 1577-1583, 2004.
11. Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, and Beck WT. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res 64: 1247-1251, 2004.
12. El-Hefnawy T, Manna PR, Luconi M, Baldi E, Slotte JP, and Huhtaniemi I. Progesterone action in a murine Leydig tumor cell line (mLTC-1), possibly through a nonclassical receptor type. Endocrinology 141: 247-255, 2000.
13. Gil S, Saura R, Forestier F, and Farinotti R. P-glycoprotein expression of the human placenta during pregnancy. Placenta 26: 268-270, 2005.
14. Gonzalez-Arenas A, Villamar-Cruz O, Guerra-Araiza C, and Camacho-Arroyo I. Regulation of progesterone receptor isoforms expression by sex steroids in the rat lung. J Steroid Biochem Mol Biol 85: 25-31, 2003.
15. Gupta A, Zhang Y, Unadkat JD, and Mao Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 310: 334-341, 2004.
16. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, and Sugimoto Y. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 64: 610-618, 2003.
17. Imai Y, Ishikawa E, Asada S, and Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 65: 596-604, 2005.
18. Jiang SW, Lloyd RV, Jin L, and Eberhardt NL. Estrogen receptor expression and growth-promoting function in human choriocarcinoma cells. DNA Cell Biol 16: 969-977, 1997.
19. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, and Schinkel AH. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92: 1651-1656, 2000.
20. Khan-Dawood FS and Dawood MY. Estrogen and progesterone receptor and hormone levels in human myometrium and placenta in term pregnancy. Am J Obstet Gynecol 150: 501-505, 1984.
21. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, and Schellens JH. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20: 2943-2950, 2002.
22. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61: 3458-3464, 2001.
23. Mathias AA, Hitti J, and Unadkat JD. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol 289: R963-R969, 2005.
24. Merino G, van Herwaarden AE, Wagenaar E, Jonker JW, and Schinkel AH. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol Pharmacol 67: 1765-1771, 2005.
25. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, and Bates SE. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59: 8-13, 1999.
26. Reed CA, Berndtson AK, and Nephew KP. Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor-alpha expression in the rat uterus. Anticancer Drugs 16: 559-567, 2005.
27. Revelli A, Massobrio M, and Tesarik J. Nongenomic actions of steroid hormones in reproductive tissues. Endocr Rev 19: 3-17, 1998.
28. Richter TA, Robinson JE, and Evans NP. Progesterone blocks the estradiol-stimulated luteinizing hormone surge by disrupting activation in response to a stimulatory estradiol signal in the ewe. Biol Reprod 67: 119-125, 2002.
29. Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, and Bates SE. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 1512: 171-182, 2001.
30. Schwarzenbach H, Manna PR, Stocco DM, Chakrabarti G, and Mukhopadhyay AK. Stimulatory effect of progesterone on the expression of steroidogenic acute regulatory protein in MA-10 Leydig cells. Biol Reprod 68: 1054-1063, 2003.
31. Sharma SC, Clemens JW, Pisarska MD, and Richards JS. Expression and function of estrogen receptor subtypes in granulosa cells: regulation by estradiol and forskolin. Endocrinology 140: 4320-4334, 1999.
32. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ III, Gilbertson R, Germain GS, Harwood FC, and Houghton PJ. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64: 7491-7499, 2004.
33. Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Greco WR, Ross DD, and Baer MR. Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function. Leukemia 18: 1252-1257, 2004.
34. Tanaka Y, Slitt AL, Leazer TM, Maher JM, and Klaassen CD. Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem Biophys Res Commun 326: 181-187, 2005.
35. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, and Schinkel AH. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine. Cancer Res 63: 6447-6452, 2003.
36. Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD, and Schneider E. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 60: 3514-3521, 2000.